Jefferies has previously said that its sales projections for Bimzelx have been capped by a psoriasis market dominated by competitors with large marketing budgets, and speculated that UCB may opt ...

ATLANTA, March 7, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced further long-term data from the Phase 3 trials, and their open-label extensions, investigating ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB’s Bimzelx achieved complete skin clearance. After five years of continued ...

On Friday, UCB SA (OTC:UCBJY) (OTC:UCBJF) announced further long-term data from the Phase 3 trials and their open-label extensions, investigating Bimzelx (bimekizumab) in adults with moderate-to ...

UCB released two-year data from the BE HEARD trials for Bimzelx in moderate to severe hidradenitis suppurativa (HS). In 425 HS patients with ≥1 draining tunnels (DTs) at baseline, 55.7% (195/350 ...

BIMZELX ® is the first and only approved medicine designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F) (PRNewsfoto/UCB, Inc.) "A primary treatment goal for ...

"A primary treatment goal for people living with psoriasis is durable, high rates of complete skin clearance. These five-year bimekizumab-bkzx results provide valuable evidence for clinical ...

On Friday, UCB SA (OTC:UCBJY) (OTC:UCBJF) announced further long-term data from the Phase 3 trials and their open-label extensions, investigating Bimzelx (bimekizumab) in adults with ...

Sustained complete skin clearance over five years: In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% of patients with moderate-to-severe plaque psoriasis (PSO) treated with ...

BIMZELX ® is the first and only approved medicine designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F) (PRNewsfoto/UCB, Inc.) "A primary treatment goal for people ...